New warnings have been added to the prescribing information for the Alzheimer's drug Aricept (donepezil) advising of the risk of two rare but potentially serious conditions: muscle breakdown ...

SYDNEY -- Parkinson's disease patients who have impaired cognition appeared to benefit from the Alzheimer's disease medicine donepezil (Aricept) -- with no detriment to their motor skills, researchers ...

Review the side-effects of Donepezil as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Donepezil (Aricept, Esai) slows atrophy of the hippocampus in patients with prodromal Alzheimer's disease, a new randomized study shows. "After 1 year we were surprised to see a 42% reduction of ...

Donepezil, marketed under the brand name Aricept, is an oral tablet medication prescribed for people living with Alzheimer’s disease. Medicare drug plans may cover the brand drug Aricept or its ...

October 8, 2010 — The acetylcholinesterase inhibitor donepezil (Aricept, Pfizer), used primarily to treat Alzheimer's disease (AD), significantly reduced the number of falls in Parkinson's disease (PD ...

Woodcliff Lake, NJ, and New York, July 23, 2010 - Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept ...

Please provide your email address to receive an email when new articles are posted on . The off-label use of donepezil did not improve cognitive ability scores in patients with an early onset form of ...

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Aricept ® Patch ...

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults. Last reviewed: 20 June 2018. This ...

Researchers have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the ß-amyloid protein, involved in Alzheimer's ...

NICE has today (23 March 2011) issued updated guidance to the NHS on the use of four drugs to help manage Alzheimer´s disease. The updated guidance extends previous recommendations for the use of ...